Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7001566 | 0.86 | NOTUM (0.46) | SLC6A2SLC6A4CYP2D6SLC6A3KMT2A | |
| SCHEMBL2073882 | 0.83 | SLC6A2 (0.46) | SLC6A2SLC6A4NOTUMHTR2AHRH1 | |
| SCHEMBL20680819 | 0.82 | L3MBTL1 (0.45) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2074265 | 0.81 | SLC6A2 (0.47) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2074192 | 0.79 | SLC6A2 (0.57) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20680868 | 0.74 | SLC6A2 (0.43) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL6999610 | 0.73 | NOTUM (0.45) | NOTUMHTR1AHTR2CDRD3HTR2B | |
| SCHEMBL7002593 | 0.73 | SLC6A2 (0.48) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27010071 | 0.72 | NOTUM (0.55) | CYP2C19NOTUMHTR2CDRD3HTR2B | |
| SCHEMBL2071536 | 0.69 | SLC6A2 (0.63) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1756054-B1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-1756054-B1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | TPH1, HTR1A, HTR3A | SLC6A2 9/4885SLC6A4 14/4885CYP1A2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.